Mackenzie Financial Corp Acquires New Stake in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Mackenzie Financial Corp acquired a new stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 12,338 shares of the company’s stock, valued at approximately $28,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Marathon Trading Investment Management LLC bought a new stake in shares of G1 Therapeutics in the 2nd quarter worth $46,000. XTX Topco Ltd increased its holdings in shares of G1 Therapeutics by 104.0% in the 2nd quarter. XTX Topco Ltd now owns 21,020 shares of the company’s stock worth $48,000 after purchasing an additional 10,718 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of G1 Therapeutics in the 2nd quarter worth $48,000. SG Americas Securities LLC bought a new stake in shares of G1 Therapeutics in the 1st quarter worth $58,000. Finally, Rhumbline Advisers increased its holdings in shares of G1 Therapeutics by 5,136.0% in the 2nd quarter. Rhumbline Advisers now owns 50,632 shares of the company’s stock worth $115,000 after purchasing an additional 49,665 shares in the last quarter. Institutional investors own 24.21% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on GTHX shares. Wedbush lowered G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. HC Wainwright lowered G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of G1 Therapeutics in a report on Wednesday, August 7th.

G1 Therapeutics Stock Performance

GTHX stock opened at $7.15 on Wednesday. The company has a market cap of $373.81 million, a P/E ratio of -11.53 and a beta of 1.66. G1 Therapeutics, Inc. has a 1 year low of $1.08 and a 1 year high of $7.19. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 2.12. The stock’s fifty day moving average price is $6.76 and its 200-day moving average price is $4.78.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The firm had revenue of $16.55 million for the quarter, compared to the consensus estimate of $15.88 million. G1 Therapeutics had a negative return on equity of 136.98% and a negative net margin of 76.93%. On average, equities analysts forecast that G1 Therapeutics, Inc. will post -0.45 earnings per share for the current year.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.